Olink Holding AB (publ) (OLK)
|Net Income (ttm)||n/a|
|Trading Day||June 17|
|Day's Range||31.00 - 33.09|
|52-Week Range||25.55 - 42.20|
Olink: SCALLOP launches clinical trial arm to uncover next level of drug target insights from proteomic profiling
UPPSALA, Sweden, June 15, 2021 (GLOBE NEWSWIRE) -- Scallop-logo-470-pxOlink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the SCALLOP consortium (Systematic and Combined AnaLysis of Ol...
Announcing Olink Signature Q100: facilitating access for researchers to Olink technology with a benchtop system dedic...
UPPSALA, Sweden, June 02, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that it is now taking orders for Olink® Signature Q100, to allow more researchers access to Olink...
UPPSALA, Sweden, May 25, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that it will be participating in the Goldman Sachs 42nd Annual Global Healthcare Confere...
UPPSALA, Sweden, May 20, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its financial results for the first quarter of 2021.
UPPSALA, Sweden, April 29, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK), a global leader in proteomics, today announced that it will release financial results for the first quarter of...
Olink Holding AB (publ) (Nasdaq: OLK) (“Olink” or the “Company”), today announced the pricing of its...
Olink Holding, which provides a platform of proteome analysis products for biomedical research, filed on Wednesday with the SEC to raise up to $100 million in a US initial public offering.
Olink Holding AB (publ) has filed to go public with an IPO on the NASDAQ.
Our purpose is to enable and accelerate the field of proteomics by providing a platform of products and services that are deployed across major biopharmaceutical companies and leading clinical and academic institutions, to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. We support 30 of the world’s largest 40 biopharmaceutical companies by 2019 revenue, including all of the largest 19, and many leading academic institutions. Our current offering is based on our pr... [Read more...]
Diagnostics & Research
|IPO Date |
Mar 25, 2021
|Stock Exchange |
|Ticker Symbol |
In 2020, Olink Holding's revenue was $54.07 million, an increase of 29.68% compared to the previous year's $41.69 million. Losses were -$6.78 million, -62.08% less than in 2019.